0001813747-20-000001.txt : 20200618 0001813747-20-000001.hdr.sgml : 20200618 20200618152842 ACCESSION NUMBER: 0001813747-20-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b ITEM INFORMATION: Investment Company Act Section 3(c) ITEM INFORMATION: Section 3(c)(1) FILED AS OF DATE: 20200618 DATE AS OF CHANGE: 20200618 EFFECTIVENESS DATE: 20200618 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Solas BioVentures Fund II, LP CENTRAL INDEX KEY: 0001813747 IRS NUMBER: 850627769 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-369247 FILM NUMBER: 20972206 BUSINESS ADDRESS: STREET 1: 835 GEORGIA AVENUE STREET 2: SUITE 800 CITY: CHATTANOOGA STATE: TN ZIP: 37402 BUSINESS PHONE: (423) 648-7894 MAIL ADDRESS: STREET 1: 835 GEORGIA AVENUE STREET 2: SUITE 800 CITY: CHATTANOOGA STATE: TN ZIP: 37402 D 1 primary_doc.xml X0708 D LIVE 0001813747 Solas BioVentures Fund II, LP 835 GEORGIA AVENUE SUITE 800 CHATTANOOGA TN TENNESSEE 37402 (423) 648-7894 DELAWARE None None Limited Partnership true 2020 Mark N/A Hackett 835 GEORGIA AVENUE SUITE 800 CHATTANOOGA TN TENNESSEE 37402 Executive Officer Promoter Manager of Solas BioVentures Management LLC, the Investment Manager of the Issuer Michael N/A Hoey 835 GEORGIA AVENUE SUITE 800 CHATTANOOGA TN TENNESSEE 37402 Executive Officer Promoter Manager of Solas BioVentures Management LLC, the Investment Manager of the Issuer Charles David Adair 835 GEORGIA AVENUE SUITE 800 CHATTANOOGA TN TENNESSEE 37402 Executive Officer Promoter Manager of Solas BioVentures Management LLC, the Investment Manager of the Issuer N/A N/A Solas Partners II, LLC 835 GEORGIA AVENUE SUITE 800 CHATTANOOGA TN TENNESSEE 37402 Promoter General Partner of Issuer N/A N/A Solas BioVentures Management, LLC 835 GEORGIA AVENUE SUITE 800 CHATTANOOGA TN TENNESSEE 37402 Promoter Investment Manager of Issuer Pooled Investment Fund Venture Capital Fund false Decline to Disclose 06b 3C 3C.1 false 2020-06-05 false true false 500000 Indefinite 5150000 Indefinite false 13 0 true 0 true 50000 true The Issuer's organizational expenses will be reimbursed by the Issuer to the General Partner and/or Investment Manager. The Investment Manager will receive an annual management fee from the Issuer as described in the Issuer's offering documents false Solas BioVentures Fund II, LP Mark Hackett Mark Hackett Manager 2020-06-18